Search - tctmd.com

Displaying 581 - 600 of 619

Sort: Relevancy | Date

News Daily News

JACC Viewpoint: Studies Needed on Long-term Consequences of ‘Silent’ Cerebral Infarcts

L.A. McKeown

October 03, 2012

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

Presentation

Systemic Review and Adjusted Indirect Comparison Meta-analysis of Oral Anticoagulants in A-fib

Presenter: 89964|William Baker

September 10, 2012

News Daily News

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

August 14, 2012

News Daily News

Indirect Comparisons Show Little Difference Among New Anticoagulants

August 14, 2012

Presentation

Indirect Comparisons of New Oral Anticoagulant Drugs When Used for Stroke Prevention in A-fib

Presenter: GYH Lip

August 13, 2012

Presentation

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Presenter: M. Lamberts

August 10, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Caitlin E. Cox

July 16, 2012

News Daily News

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Caitlin E. Cox

July 16, 2012

Presentation

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Presenter: 204943|JM Ruiz-Nodar

July 13, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Presenter: Robert G. Hart

April 27, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

Advertisement

JACC Viewpoint: Studies Needed on Long-term Consequences of ‘Silent’ Cerebral Infarcts

Dabigatran Usage up, Both for A-fib and Off-Label Indications

Systemic Review and Adjusted Indirect Comparison Meta-analysis of Oral Anticoagulants in A-fib

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

Indirect Comparisons Show Little Difference Among New Anticoagulants

Indirect Comparisons of New Oral Anticoagulant Drugs When Used for Stroke Prevention in A-fib

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in A-fib Patients Following MI and PCI

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Oral Anticoagulation Therapy in A-Fib Pts at High Bleeding Risk Undergoing Coronary Artery Stenting

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Rivaroxaban May be Cost-Effective for A-fib Patients

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Watchman Works Just as Well Without Warfarin-Protected Transition

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content